bluebird bio Inc. (BLUE)

bluebird bio Inc. (BLUE)
- View BLUE Profile
- View Questions on BLUE

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

bluebird bio Inc. (BLUE)
- View BLUE Profile
- View Questions on BLUE
CRISPR Therapeutics AG (CRSP $65.93)
- $65.93 Cap: $5.64B
- View CRSP Profile
- View Questions on CRSP

Q: If you were to invest in the gene editing space, how would you rank these two?

Read Answer Asked by Jim on December 11, 2023

bluebird bio Inc. (BLUE)
- View BLUE Profile
- View Questions on BLUE

Q: Peter; Could you updates your thoughts on BLUE ? Thanks
Rod

Read Answer Asked by Rodney on January 23, 2023

bluebird bio Inc. (BLUE)
- View BLUE Profile
- View Questions on BLUE
Invitae Corporation (NVTA)
- Cap: $5M
- View NVTA Profile
- View Questions on NVTA
Guardant Health Inc. (GH $46.25)
- $46.25 Cap: $5.65B
- View GH Profile
- View Questions on GH

Q: Hi team,

Grateful for your views on Oncorus (oncr-a). Apparently, the CEO was previously head of oncology at Moderna. Any other favorites for growth in the field of immunotherapy ?

With great appreciation for your work,

Jacques IDS

Read Answer Asked by Jacques on May 04, 2021